Risankizumab bests adalimumab in plaque psoriasis

At four months, most patients had a 90% response with the IL-23 inhibitor

The anti-interleukin-23 monoclonal antibody risankizumab is more effective for treating plaque psoriasis than the TNF-alpha inhibitor adalimumab, according to a clinical trial.